Mizuho lowered the firm’s price target on Abbott to $105 from $115 and keeps a Neutral rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- DexCom initiated with an Outperform at Leerink
- Options Volatility and Implied Earnings Moves This Week, October 16 – October 20, 2023
- ABT Earnings this Week: How Will it Perform?
- Abbott price target lowered to $112 from $120 at Jefferies
- Abbott price target lowered to $122 from $130 at Citi
Questions or Comments about the article? Write to editor@tipranks.com